Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto CAR-T for Relapsed/Refractory NHL
NCT04666168Recruiting
- Sponsor
- Senlang Bio
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in non-Hodgkin lymphoma (NHL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Started Oct 2020; status: recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04666168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666168.